Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
The Challenge Inbeeo’s client, a local affiliate of a major global pharmaceutical company, is developing several gene therapy (GTx) products. In advance of their launch
The Challenge Inbeeo’s client, a global leader in chronic disease, is embarking on an exciting journey to develop cell therapies in four indications. Whilst an
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
